Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Molecular Pharmacology, 74 , 17221728
About the Promotional Language in This Article's Title If you landed here from an Omzo ad, you probably recognize some of the language in this article's title and opening
Bujko, K
Sanofi presents results from the first head-to-head study comparing Toujeo to insulin degludec - Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin - Incidence and rate of low blood sugar events were reduced with Toujeo in the first 12 weeks compared to insulin degludec, and comparable from weeks 13-24 and the full 24-week study period News provided by Sanofi Jun 25, 2018, 08:01 ET ORLANDO, Fla., June 25, 2018 /PRNewswire/ -- Sanofi (NYSE: SNY
Hawkins, C
US$ 21.36
US$ 27.51
US$ 28.87
US$ 26.58
US$ 20.09
